The Correlation Between the Metabolism and the Functional Status of Multiple Organs in the Early Stage of Diquat Poisoning
NCT05168111 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2021-12-23
Summary
Diquat (DQ), as a conductive biocidal herbicide, is classified as medium according to Chinese pesticide toxicity classification standards. Since the sale and use of paraquat are stopped in 2016, incidents of diquat poisoning have begun to increase. Diquat is very toxic to the human body. Mistake of Diquat can cause damage to multiple organs throughout the body. It has a high fatality rate and no specific treatment.The treatment method has become a research hotspot of modern poisoning treatment.
The degree of organ dysfunction caused by DQ poisoning is mainly related to the patient's intake and the distribution of the poison in the human body.So far, the distribution concentration of DQ under the influence of the time gradient in the body and the influence of DQ on the human environment,metabolimics,,immune regulation activity and the comprehensive mechanism of action of various inflammatory factors have not been fully elucidated. Therefore, this research mainly focuses on analyzing the internal environment metabolism research in patients with DQ poisoning, and to conduct exploratory research on the severity of the impact on their organ functions
Conditions
- Diquat Poisoning
Interventions
- DIAGNOSTIC_TEST
-
Detect the serum sample
Detect the serum sample
Sponsors & Collaborators
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
lead OTHER
Principal Investigators
-
Yongan Xu · SAHZU
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-12-02
- Primary Completion
- 2022-06-30
- Completion
- 2022-06-30
Countries
- China
More Related Trials
-
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
NCT02576327 ·Status: UNKNOWN ·Phase: PHASE4
-
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
NCT00553059 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
NCT00503386 ·Status: COMPLETED ·Phase: PHASE2
-
Dexamethasone Dose for Postoperative Nausea and Vomiting Prophylaxis in Obese Patients
NCT04538820 ·Status: UNKNOWN ·Phase: PHASE4
-
The Efficacy of Dexamethasone in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae Due to Carbon Monoxide Poisoning
NCT06811675 ·Status: RECRUITING ·Phase: PHASE4
-
Antiemetic Efficacy and Safety of Dexamethasone in Obstetric Surgical Patients
NCT01028547 ·Status: COMPLETED ·Phase: NA
-
Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC
NCT05711823 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
NCT00424242 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
NCT00152867 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects
NCT00954291 ·Status: UNKNOWN
-
Study of HR20013 for Injection in Patients With Malignant Solid Tumors
NCT05465681 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Chemotherapy-related Hiccups With Baclofen
NCT03778281 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy
NCT00359567 ·Status: COMPLETED ·Phase: PHASE3
-
Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy
NCT00096187 ·Status: TERMINATED ·Phase: PHASE2
-
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
NCT01909856 ·Status: COMPLETED ·Phase: PHASE2
-
Methylprednisolone Replacement for Dexamethasone-induced Hiccup
NCT01277731 ·Status: WITHDRAWN ·Phase: NA
-
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
NCT00869310 ·Status: TERMINATED ·Phase: PHASE3
-
Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.
NCT05755659 ·Status: UNKNOWN ·Phase: NA
-
The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV
NCT05690802 ·Status: RECRUITING ·Phase: NA
-
Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation
NCT01974024 ·Status: COMPLETED ·Phase: PHASE3
-
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
NCT06200168 ·Status: RECRUITING ·Phase: PHASE3
-
Treatment Algorithm for Nausea and Vomiting in the Palliative Phase
NCT03017391 ·Status: UNKNOWN ·Phase: PHASE4
-
HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
NCT06554184 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Prophylactic Antiemetic Dexamethasone on Plasma Cortisol Levels
NCT01524731 ·Status: COMPLETED ·Phase: NA
-
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
NCT03601871 ·Status: UNKNOWN ·Phase: NA